Cutting Psoriasis Biologic Spend Without Cutting Outcomes
Six years of converging clinical trial data just answered the question “is biologic dose reduction safe in psoriasis”
Six years of converging clinical trial data just answered the question “is biologic dose reduction safe in psoriasis”. Here's the financial case for health plan finance and procurement teams to act on it now.
Psoriasis and eczema biologic spend has become one of the fastest-growing line items in health plan specialty drug costs. As a result, these drugs also are a top priority in health plan pharmacy cost management.
However, specialty drug cost management solutions need to reduce cost without putting member outcomes at risk. But, following clinical and consensus data over the last six years, safety and efficacy data on biologic dose reduction in psoriasis is proven.
For health plan finance and procurement leaders, it's no longer a question of whether reducing treatment in certain cases is clinically beneficial. It's whether you're properly set up to capture the savings and operationally implement a cost-savings solution that’s effective, efficient, and not resource contingent.
If you’re searching for specialty pharmacy spend reduction strategies but overlooking structured dose reduction, or are concerned the operational risk is too great, a new benefit for your members is proven to both improve outcomes and reduce total psoriasis biologic cost.
A Worthwhile Approach to Implementing Biologic Dose Reduction Strategy
The evidence of biologic dose reduction has been converging for six years and just reached critical mass. Six independent research teams across four continents have landed on the same conclusion that in many patients, it's a safe and effective way to reduce treatment intensity, with a direct impact on cost reduction.
Zest Health developed a biologic stewardship program that has turned this clinical evidence and consensus on biologic dose reduction into measured operational impact and financial results for health plans.
Health plans who partner with Zest to offer its dermatology care benefit, have seen:
- 3.1:1 return on investment
- $17,000+ in annual net savings per enrolled member (PEPY)
- 53% of eligible members successfully deprescribed to a lower-intensity, lower-cost regimen without compromising disease control
Run that per-member savings figure across your psoriasis and eczema biologic population, and it stops looking like a line item and starts looking like a number worth a conversation.
Benefit Program Purpose-Built for Cost-Savings
While the specialty drug savings from biologic dose reduction are clear, the operational lift can be intimidating and cause health plans to stall.
Zest Health’s value-based dermatology program makes implementing a cost-saving solution streamlined, quick, and easy. Zest Health does not rely on your team to build a new infrastructure, retain clinical staff, or renegotiate provider contracts.
It is a full-service clinical dermatology model that includes the technology, protocols, and providers to deliver high-quality psoriasis and eczema care that ensures members are on the right size treatment.
Zest’s chronic disease model includes:
- Standardized reassessment and deprescribing protocols, already validated against national and international consensus criteria
- 6-week implementation timeline for health plans, from contract to first cohort live
- Board-certified clinical dermatologists who virtually treat enrolled members
- Minimal internal lift: Zest's care team handles patient identification, clinical monitoring, and reassessment; your team handles the budget line
- Communication support, including support enrolling eligible members and ensuring continuity of care
Act Fast Before Runaway Costs Outpace the Fix
As the clinical evidence hardens, and it just did in 2026, more health plans will move to operationalize dose reduction. The plans capturing savings today are locking in a full budget cycle's head start over the ones still waiting for a case study to convince them. We already have.
The clinical debate is over, and the time is now. The only question left is whether you're going to partner with a company able to secure you meaningful returns with limited resource impact or not.
